Goldman Sachs’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-19,100
| Closed | -$89K | – | 6624 |
|
|
2017
Q4 | $89K | Sell |
19,100
-9,500
| -33% | -$52.4K | ﹤0.01% | 5778 |
|
|
2017
Q3 | $203K | Sell |
28,600
-6,800
| -19% | -$48.9K | ﹤0.01% | 5745 |
|
|
2017
Q2 | $256K | Buy |
35,400
+25,500
| +258% | +$159K | ﹤0.01% | 5634 |
|
|
2017
Q1 | $61K | Sell |
9,900
-28,400
| -74% | -$156K | ﹤0.01% | 6236 |
|
|
2016
Q4 | $224K | Buy |
38,300
+12,000
| +46% | +$65.6K | ﹤0.01% | 5690 |
|
|
2016
Q3 | $140K | Sell |
26,300
-84,900
| -76% | -$458K | ﹤0.01% | 6056 |
|
|
2016
Q2 | $736K | Sell |
111,200
-99,900
| -47% | -$559K | ﹤0.01% | 4479 |
|
|
2016
Q1 | $986K | Buy |
211,100
+189,900
| +896% | +$758K | ﹤0.01% | 4086 |
|
|
2015
Q4 | $107K | Hold |
21,200
| – | – | ﹤0.01% | 6146 |
|
|
2015
Q3 | $75K | Sell |
21,200
-398,800
| -95% | -$2.67M | ﹤0.01% | 6633 |
|
|
2015
Q2 | $4.19M | Buy |
420,000
+100,500
| +31% | +$1.08M | ﹤0.01% | 3120 |
|
|
2015
Q1 | $4.07M | Buy |
319,500
+305,500
| +2,182% | +$3.93M | ﹤0.01% | 3095 |
|
|
2014
Q4 | $198K | Sell |
14,000
-143,800
| -91% | -$2.23M | ﹤0.01% | 6164 |
|
|
2014
Q3 | $2.17M | Buy |
157,800
+117,900
| +295% | +$1.8M | ﹤0.01% | 3856 |
|
|
2014
Q2 | $614K | Sell |
39,900
-67,300
| -63% | -$954K | ﹤0.01% | 5133 |
|
|
2014
Q1 | $1.83M | Sell |
107,200
-329,700
| -75% | -$4.97M | ﹤0.01% | 4064 |
|
|
2013
Q4 | $5.66M | Buy |
436,900
+50,000
| +13% | +$597K | ﹤0.01% | 2952 |
|
|
2013
Q3 | $3.9M | Hold |
386,900
| – | – | ﹤0.01% | 3206 |
|
|
2013
Q2 | $2.89M | Buy |
+386,900
| New | +$3.02M | ﹤0.01% | 3326 |
|
Goldman Sachs's KERX Position: Q4 2018 in Review
Goldman Sachs sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 70,113 shares — an estimated $238K sold.
Goldman Sachs first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $7.74M in Q3 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Goldman Sachs reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Goldman Sachs sold 70,113 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $238K.
- Goldman Sachs first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Goldman Sachs's Keryx Biopharmaceuticals Inc position peaked at $7.74M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Goldman Sachs's 13F filing for Q4 2018, filed 14 Feb 2019.